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INTRODUCTION	
	
Mitral	valve	regurgitation	(MR)	is	the	second	most	frequent	valve	disease	requiring	invasive	
treatment	in	the	Western	world1.	Significant	functional	mitral	regurgitation	(FMR)	can	be	found	in	
around	30%	of	the	patients	with	previous	myocardial	infarction	(MI)	and	in	35%	of	the	patients	
with	chronic	heart	failure	(HF).	Data	from	many	observational	studies	showed	a	twofold	mortaliy	
rate	in	advanced	HF	with	severe	MR2-4.	
MR	can	derive	from	anatomo-structural	or	functional	changes	of	the	components	of	the	
valve	apparatus.	FMR	is	due	to	changes	of	the	valve	apparatus	following	left	ventricle	(LV)	
remodeling	5-7.	Etiopathogenesis	of	FMR	can	be	classified	as	“ischemic”	or	“non	ischemic”.	In	the	
former,	the	major	determinant	of	MR	is	valve	tethering,	i.e.	the	downward	strecthing	of	both	valve	
leaflets	due	to	LV	dilatation	and	increase	of	sfericity	index2.	These	two	factors	cause	the	apical	
displacement	of	papillary	muscles	and	the	lateral	displacement	of	closure	forces	acting	on	the	
leaflets.	As	a	consequence,	there	is	incomplete	coaptation	of	mitral	valve	leaflets	and	MR.	Chronic	
LV	volume	overload	causes	an	increase	of	LV	wall	stress,	that	in	turn	cause	a	progressive	reduction	
of	ventricular	contractility	and	annular	closure	forces,	further	increasing	MR	volume.	The	most	
important	mechanism	of	ischemic	FMR	is	tethering	of	a	single	valve	leaflet,	which	is	caused	by	
displacement	of	the	papillary	muscle	located	in	the	infarcted	zone,	where	LV	remodeling	occurs8.	
Independently	from	etiology,	LV	remodeling	secondary	to	chronic	volume	overload	is	directly	
responsible	of	FMR	and	its	progression,	because	of	the	vicious	circle	between	volume	overload	
and	LV	remodeling	(figure	1).	
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																			Figure	1:	Etiology	of	functional	mitral	regurgitation			
		
Surgical	therapy	of	MR	in	advanced	HF	is	still	object	of	controversy.	It	has	been	shown	that,	when	
irreversible	LV	remodeling	and	pulmonary	hypertension	occur,	reduction	of	MR	grade	is	not	
associated	with	any	benefit	6,9.	A	number	of	studies	identified	reduced	LV	ejection	fraction	(EF)		as	
an	independent	negative	prognostic	factor	following	mitral	valve	surgery6,10.	On	the	other	hand,	
there	is	evidence	showing	that	treatment	of	MR	in	patients	with	severe	LV	dysfunction	is	
associated	with	a	significative	reverse	LV	remodeling	(increase	of	EF,	reduction	of	telesystolic	and	
telediastolic	volumes	and	sfericity	index),	improvement	of	functional	class	and	quality	of	life6.	Yet,	
patients	with	advanced	HF	and	extreme	LV	remodeling	exhibit	very	high	peri-	and	post-operative	
mortalty	and,	for	many	of	these	patients,	surgical	risk	is	deemed	prohibitive.	
Percutaneous	mitral	valve	repair	represent	a	therapeutic	option	in	alternative	to	
conventional	cardiac	surgery	in	a	selected	patient	population,	comprising	mainly	subjects	who	are	
not	candidate	to	cardiac	surgery	because	of	a	too	high	or	prohibitive	surgical	risk,	caused	by	
comorbidity,	advanced	age	or	severe	LV	dysfunction.	Based	on	these	premises,	several	devices	for	
transcatheter	treatment	of	MR	have	been	developed	and	are	under	investigation.	All	these	
devices	aim	at	reproducing		conventional	surgical	techniques	for	mitral	valve	repair:	edge-to-edge	
technique,	indirect	anuloplasty	using	a	device	positioned	in	the	coronary	sinus,	direct	anuloplasty,	
LV	remodeling	with	transventricular	or	transatrial	devices,	mitral	valve	replacement.	Presently,	the	
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only	percutaneous	device	with	CE	market	approval	is	the	MitraClip	system	(Abbott	Vascular,	
Abbott	Park,	Illinois,	USA).	The	Mitraclip	procedure	consists	in	positioning	a	clip	which	captures	
both	valve	leaflets	at	the	level	of	mitral	regurgitation.	This	generate	a	new	permanent	coaptation	
point	between	the	two	leaflets	and	valve	opening	with	a	double	orifice,	determining	reduction	of	
MR	grade	similarly	with	the	surgical	edge-to-edge		technique	first	described	by	Alfieri11.	
Positioning	and	release	of	the	device	is	performed,	under	general	anesthesia	and	
transoesophageal	echocardiography	guide,	through	a	catheter	introduced	in	the	right	femoral	vein	
and	reaching	the	valve	through	the	interatrial	septum.	To	date,	more	than	10.000	percutaneous	
mitral	valve	repair	procedures	with	the	Mitraclip	system	have	been	performed	worldwide.		
The	first	clinical	data	come	from	the	North-American	EVEREST	trials	12,13,	followed	by	several	
clinical	European	registries	that	have	been	launched	after	CE	market	approval.	Data	from	EVEREST	
I	and	II	trials	showed	feasibility	and	safety	of	percutaneous	mitral	valve	repair	with	the	Mitraclip	
system,	which	was	associated	with	a	low	mortality	and	morbility	rate	in	the	perioperative	phase	
and	during	follow-up12,13.	Subsequently,	the	results	of	the	randomized	controlled	EVEREST	trial	
have	been	reported	14.	This	trial	compared	in	a	randomized	2:1	fashion	184	patients	treated	with	
the	Mitraclip	system	with	95	patients	undergoing	surgical	MV	repair.	All	patients	had	MR	grade	≥	
3+	and	were	eligible	to	both	treatments.	The	study	reported	a	significant	reduction	of	adverse	
events	in	patients	receiving	the	MitraClip	procedure	(15%)	vs.	those	who	underwent	surgery	(48%,	
p<	0.0001),	whereas	procedural	success	and	long-term	efficacy	in	terms	of	reduction	of	MR	grade	
to	a	degree	≤	2+	were	more	commonly	achieved	in	surgical	patients	(73%)	in	comparison	with	the	
percutaneous	treatment	arm	(55%).	Inverse	LV	remodeling	has	been	observed	in	both	treatment	
arms,	whilst	in	the	Mitraclip	group	there	was	a	better	recover	of	functional	class	and	quality	of	life.	
Data	from	the	“real	world”	15-18	demonstrate	that	patients	treated	with	the	Mitraclip	procedure	
have	a	higher	risk	in	comparison	with	patients	enrolled	in	the	EVEREST	study,	showing	that	this	
procedure	is	feasible	and	safe	in	patients	that	would	have	been	excluded	based	on	the	strict	
enrollment	criteria	of	the	trial.	In	all	real	world	series,	patients	who	underwent	the	Mitraclip	
procedure	had	predominantly	functional	rather	than	degenerative	MR,	with	reduced	LV	function	
and	a	higher	surgical	risk	profile.	
Based	on	available	evidence,	current	indications	for	Mitraclip	MV	repair	are	the	presence	
of	symptomatic	MR	grade	≥3+,	of	degenerative	or	functional	etiology,	in	patients	with	very	high	of	
prohibitive	surgical	risk.	Surgical	risk	assessment	is	complex,	and	requires	a	multidisciplinary	
approach	within	a	heart	team	composed	by	cardiac	surgeons,	clinical	cardiologists,	expert	
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sonographers	and	interventional	cardiologists.	The	heart	team	express	an	opinion	on	feasibility,	
risks	and	expected	benefits	of	both	procedures,	surgical	and	percutaneous,	in	terms	of	NYHA	
functional	class	and	quality	of	life	improvement,	and	prognosis	quoad	vitam.	As	far	as	the	
Mitraclip	procedure	is	concerned,	clinical	evaluation	and	meticolous	echocardiographic	
assessment	are	key	to	perform	a	safe	and	effective	procedure.	In	particular,	trans-esophageal	
ecocardiography	(TEE)	is	necessary	to	precisely	characterize	specific	anatomic	factors	associated	
with	procedural	feasibility	and	technical	success	(figure	2).	
	
												 	
Figure	2:	Anatomic	criteria	evaluated	during	screening	trans-esophageal	echocardiography	in	patients	who	
are	candidate	to	percutaneous	mitral	valve	repair	with	the	MitraClip	system.	A:	flail	gap	(<	10	mm),	defined	
as	the	maximal	distance	between	the	leaflet	prolaxing	in	the	left	atrium	(LA)	and	the	leaflet	on	the	annular	
plane,	measured	in	4-	or	5-chamber	long-axis	view,	where	the	gap	is	larger.	B:	flail	width	(<	15	mm),	
measured	in	short-axis	view	where	the	lesion	width	is	larger.	C:	coaptation	depth	(<	11	mm),	evaluated	in	4-
chamber	or	LV	outflow	tract	view.	D:	coaptation	lenght	(≥	2	mm)	evaluated	in	4-chamber	or	LV	outflow	
tract	view.	Ao,	aorta;	LA,	left	atrium;	LV,	left	ventricle.	
	
The	MitraClip	system	(figure	3)	consists	of	a	triassial	delivery	catheter	and	an	implantable	clip.	The	
clip	delivery	system	has	a	proximal	part	with	a	24F	diameter	and	e	distal	22F	portion.	The	clip	has	
two	arms,	is	made	of	chromo/cobalt	alloy	with	a	polyesther	coating,	pre-assembled	at	the	distal	
tip	of	the	catheter.	Orientation,	positioning,	opening,	leaflets’	capture	and	release	of	the	clip	are	
controlled	by	specific	handles	located	on	the	external	portion	of	the	catheter,	which	is	fixed	on	an	
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external	sterile	metallic	support	located	on	a	small	table	at	the	level	of	the	patient’s	legs.	
	
	
	
	
	
	
	
	
	
		
							
		
Figure	3:	MitraClip	device.	
	
The	procedure	is	performed	in	a	hybrid	operative	room	or	in	the	catheterization	laboratory	under	
general	anesthesia,	with	fluoroscopic	and	TEE	guidance.	The	right	femoral	vein	is	cannulated,	and	
a	radial	artery	is	commonly	used	for	invasive	pressure	monitoring.	Trans-septal	puncture	is	then	
performed	under	TEE	guidance	to	access	the	left	atrium.	Trans-septal	puncture	must	be	located	in	
the	postero-superior	portion	of	the	fossa	ovalis,	to	allow	the	correct	positioning	of	the	clip	delivery	
system	toward	the	MV	orifice.	The	punctute	must	be	between	35	and	45	mm	above	the	mital	
valve	annulus,	in	order	to	have	enough	space	for	the	clip	to	be	correctly	oriented	with	respect	to	
the	annular	plane	and	the	jet	of	regurgitation	(Figure	4).		
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Figure	4.	Trans-esophageal	echocardiography	monitoring	during	trans-septal	puncture,	at	the	level	of	the	
postero-superior	portion	of	the	interatrial	septum,	at	a	distance	from	the	mitral	valve	annulus	plane	around	
35-40	mm.	A:	visualization	of	the	tenting	of	the	interatrial	septum	caused	by	the	Mullins	catheter	and	the	
Brockenbrough	needle	pushed	from	the	right	atrium,	in	medio-esophageal	short-axis	view	
	(45-60°),	for	a	correct	puncture	location	in	the	antero-posterior	plane.		
B:	tenting	visualization	in	bicaval	projection	at	90°,	for	a	correct	location	of	the	needle	in	the	infero-
superior	plane.	C:	measurement	of	the	distance	between	the	tenting	on	the	left	portion	of	the	interatrial	
septum	and	the	mitral	valve	plane	in	4-chamber	view	at	0°.	
	
	
All	these	manouvres	are	visualized	and	guided	by	TEE.	For	example,	trans-septal	puncture	is	
guided	through	the	visualization	of	the	“tenting”	zone,	which	is	the	septal	deformation	caused	by	
the	Mullins	catheter	pushed	in	the	fossa	ovalis.	TEE	also	allows	the	visualization	of	the	guiding	
catheter,	the	monitoring	of	clip	insertion	in	the	left	atrium,	avoiding	trauma	and	perforation	of	the	
atrial	walls	or	the	appendage,	and	finally	guide	the	orientation	of	the	clip	perpendicularly	to	the	
mitral	valve	annulus,	centered	in	the	direction	of	the	regurgitant	jet.	The	right	clip	trajectory	and	
its	perpendicularity	with	the	rim	of	coaptation	of	the	valve	leaflets	is	constantly	verified	through	a	
number	of	projections	which	are	perpendicular	to	each	other.	Tridimensional	echocardiography,	if	
available,	represents	a	valid	support	for	the	operators,	mainly	for	the	clip	orientation,	allowing	an	
immediate	visualization	of	the	device	in	relationship	with	copatation	rim	(Figure	5).	
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Figure	5:	Tridimensional,	real	time	trans-esophageal	echocardiography	images	acquired	during	clip	
orienting	on	the	mitral	valve	plane.	A:	incorrect,	too	anterior,	position	of	the	clip	delivery	system.	B:	correct	
position,	central	and	perpendicular	to	the	coaptation	rim.	C:	clip	orientation	not	perpendicular	to	the	
coaptation	rim	(dotted	red	line;	the	dotted	green	line	indicates	the	correct	orientation).	D:	correct	clip	
orientation	on	the	coaptation	plane,	along	the	green	line.	
	
	
When	the	device	is	correctly	oriented,	it	can	be	advanced	in	the	left	ventricle	and	retrieved	to	
capture	both	valve	leaflets	(grasping).	If	a	double	orifice	has	been	created	and	echocardiography	
confirms	the	effective	reduction	of	MR	grade	and	the	perfect	inserction	of	the	valve	leaflets	within	
the	clip,	clip	arms	are	completely	closed	and	locked	and	the	clip	is	released.	If	the	position	of	the	
clip	is	not	satisfactory	or	the	grasping	is	not	complete	or	not	effective	in	reducing	MR,	before	the	
final	release	the	clip	can	be	re-opened	and	repositioned.	When	necessary,	a	second	or	a	third	clip	
can	be	implanted	to	optimize	procedural	results,	providing	a	series	of	additional	
echocardiographic	criteria	are	satisfied.	In	general,	if	no	complications	occur,	the		patient	is	
estubated	immediately	after	the	procedure.		
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AIM	OF	THE	STUDY	
Significant	functional	mitral	regurgitation	(FMR)	is	common	in	heart	failure	(HF)	patients	with	
increased	LV	volumes	and	depressed	LV	ejection	fraction	(EF)	and		has	been	associated	with	a	
ominous	prognosis5,19.	Additionally,	perioperative	mortality	after	surgery	for		FMR	is	not	negligible,	
and	a	large	number	of	patients	with	FMR	are	judged	inoperable	or	at	high	surgical	risk	because	of	
severe	LV	dysfunction	and/or	comorbidities4,20.	
Percutaneous	mitral	valve	repair	(PMVR)	with	the	MitraClipTM	device	(Abbott,	Abbott	Park,	IL,	
USA)	has	recently	evolved	as	a	therapeutic	alternative	for	patients	with	significant	MR,	of	both	
degenerative	and	functional	origin,	whose	surgical	risk	is	considered	very	high	or	prohibitive14,16,21.		
Although	less	effective	than	surgery	in	reducing	mitral	regurgitation,	PMVR	has	been	
demonstrated	to	be	safe	and	capable	of	leading	to	significant	improvement	in	clinical	outcomes.	
Additionally,	reverse	cardiac	remodeling	at	mid-term	follow-up	has	been	reported	after	successful	
PMVR	in	patients	with	left	ventricular	dysfunction	17,22,23.		However,	few	data	are	currently	
available	on	ventricular	and	neurohormonal	changes	in	patients	with	FMR	due	to	severe	LV	
dysfunction	and	refractory,	advanced	heart	failure,	otherwise	destined	to	heart	transplant		or	
death	24.	
The	aim	of	this	study	was	to	assess	and	compare	the	effects	of	PMVR	therapy	on	clinical	
outcomes,	LV	remodeling	and	neurohormonal	changes	in	inoperable	end-stage	patients	with	
chronically	symptomatic	FMR	despite	optical	medical	/	electrical	therapy	and	severe	LV	
dysfunction.		
	
METHODS	
	
Patient	selection	
We	analyzed	the	clinical	and	echocardiographic	data	of	a	consecutive	cohort	of	patients	with	
advanced	heart	failure	and	moderate	to	severe	FMR	who	underwent	PMVR	therapy	for	significant	
symptoms	not	responding	to	optimal	medical	therapy	and	CRT.	All	patients	had	been	judged	
inoperable	by	the	local	heart	team	on	the	basis	of	extreme	cardiac	remodeling	and	/	or	the	
presence	of	several	comorbidities.	Candidates	for	PMVR	were	selected	among	patients	followed	at	
our	advanced	heart	failure	department,	within	a	comprehensive	program	which	includes	CRT,	left	
ventricular	assist	device	and	heart	transplant.	When	applicable,	CRT	had	to	be	performed	first,	and	
PMVR	was	considered	only	after	≥	6	months	of	CRT	with	persisting	New	York	Heart	Association	
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(NYHA)	functional	class	III	or	IV	despite	pharmacological	optimization22.	All	potential	candidates	
underwent		transthoracic	(TTE)	and	transesophageal	Doppler	echocardiography	(TEE).	Anatomic	
feasibility	for	PMVR	was	largely	based	on	the	Endovascular	Valve	Edge-to-Edge	REpair	Study	
(EVEREST)	criteria	for	FMR.	Surgical	risk	was	estimated	using	the	Society	of	Thoracic	Surgeons	
(STS)	score	and	the	logistic	EuroSCORE	(European	System	for	Cardiac	Operative	Risk	Evaluation),	
although	additional	clinical	and	instrumental	parameter	were	taken	into	account.	The	decision	
whether	to	proceed	with	MitraClip	implantation	was	always	taken	by	a	multidisciplinary	team	
composed	by	clinical	cardiologist,	interventional	cardiologist,	expert	echocardiographer,	cardiac	
surgeon	and	cardiac	anesthesiologist.	In	particular,	patients	with	criteria	beyond	the	EVEREST	
recommendations	were	the	object	of	an	in	depth	collegial	discussion13.	
	
Echocardiographic	examination	
The	severity	of	FMR	at	baseline	was	graded	according	to	the	American	Society	of		
Echocardiography	guidelines	25	as:	mild		1+,	moderate	2+,	moderate-to-severe	3+	and	severe	4+.	In	
addition,	the	vena	contracta	width	at	the	narrowest	portion	of	the	regurgitant	jet	was	measured	
25.		Measurement	of	LV	volumes	and	EF	were	performed	according	to	the	biplane	Simpson’s	
method	26.	The	mitral	valve	orifice	area,	when	feasible,	was	assessed	using	the	pressure	half-time	
method	27.	Systolic	pulmonary	artery	pressure	was	measured	using	the	gradient	derived	from	the	
maximal	velocity	of	tricuspid	regurgitation,	adding	5	mmHg	if	the	inferior	vena	cava	had	a	normal	
diameter	(<21mm),	10	mmHg	if	the	vena	cava	was	dilated	with	reduced	respiratory	excursions,	15	
mmHg	when	the	vena	cava	was	dilated	without	respiratory	excursions	.	Right	ventricular	
dimensions	and	contractile	function	were	also	evaluated	according	to	standardized	criteria28.	
	
Device	and	procedure	
The	MitraClip	system	has	been	previously	described	in	details	13,14.	Briefly,	it	is	a	catheter	based	
system	designed	to	perform	a	double	orifice	repair	of	the	mitral	valve.	The	system	includes	a	clip,	
a	steerable	guide	catheter,	and	a	clip	delivery	system	that	enables	positioning	and	placement	of	
the	clip	on	the	mitral	valve	leaflets,	resulting	in	permanent	leaflet	approximation.	The	procedure	
was	performed	under	general	anesthesia	under	TEE	and	fluoroscopic	guidance.	Live	real-time	3-D	
echocardiography	was	used	to	improve	the	conduct	of	the	implantation.	When	necessary,	more	
than	a	clip	was	implanted.	Procedural	success	was	defined	as	the	implantation	of	at	least	1	clip	
and	reduction	of	severity	of	mitral	regurgitation	of	at	least	1	grade.	
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Study	objectives	and	follow-up	
The	aim	of	this	study	was	to	assess	the	effect	of	PMVR	on	cardiac	remodeling,	clinical	status	and	
neurohormonal	profile	(or	BNP	plasma	levels	measurement)	at	6	months	after	procedure	in	
patients	with	severe	FMR	and	severe	LV	dysfunction	for	whom	risk	of	surgical	repair/replacement	
of	the	mitral	valve	was	prohibitive.		
	 Clinical	evaluation	was	performed	before	MitraClip	treatment,	after	30	days	and	6	months,	
or	more	frequently	if	clinically-indicated.	We	assessed	the	incidence	of	death,	myocardial	
infarction,	stroke,	conversion	to	conventional	surgical	mitral	valve	replacement	and	re-admission	
for	heart	failure.	In-hospital	outcomes	included	also	bleeding,	need	for	inotropic	drugs	and	acute	
kidney	injury.	Bleeding	was	classified	as	life-threatening	(fatal	bleeding,	bleeding	in	a	critical	organ,	
bleeding	with	severe	hemodynamic	consequences,	drop	in	hemoglobin	≥5	g/dL	or	need	for	red	
blood	cells	transfusion	≥4	units),	major	bleeding	(overt	bleeding	with	drop	in	hemoglobin	≥3	g/dL	
or	requiring	transfusion	or	causing	hospitalization	or	permanent	injury,	or	requiring	surgery),	and	
minor	bleeding	(all	other	bleedings).	Acute	kidney	injury	was	defined	as	increase	in	serum	
creatinine	≥	0.3	mg/dL	compared	with	baseline.	Trans-thoracic	echocardiography	was	performed	
at	baseline,	after	PMVR	and	planned	every	6	months	thereafter.		Main	parameters	of	interest	
were	LVEF,	LV	end-diastolic	volume	(EDV),	and	LV	end	systolic	volume	(ESV).	Pro-brain-natriuretic-
peptide	(proBNP)	plasma	level	measurements	were	performed	before	the	procedure	and	at	6	
months.		
	
	
Statistical	analysis	
	
Continuous	variables	were	expressed	as	mean	±	standard	deviation	(SD).	Categorical	variables	
were	presented	as	frequencies	and	percentages.	Paired	Student	t-tests	were	utilized	to	assess	the	
differences	in	the	means	of	continuous	variables	before	and	after	procedures.	Comparison	test	
between	proportions	were	utilized	to	assess	the	differences	in	the	categorical	variables	before	and	
after	procedure.	The	Wilcoxon	matched	pairs	signed-ranks	test	were	utilized	for	comparison	of	
BNP	value	before	and	after	procedure.	A	P	value	<	0.05	was	considered	statistically	significant.	The	
study	investigations	were	in	accordance	with	the	Declaration	of	Helsinki,	the	study	was	approved	
by	our	institutional	review	board	and	all	patients	provided	written	informed	consent	for	
participation.	
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RESULTS	
	
Baseline	characteristic	of	patient	population	
	
Between	June	2013	and	April	2015,	25	consecutive	patients	with	advanced	heart	failure	and	
severe	FMR	(60%	ischaemic	aetiology;	40%	idyopathic	dilated	cardiomyopathy)	were	evaluated.	
Baseline	patients’	characteristics	are	listed	in	Table	1.The	study	population	included	76%	men	with	
a	mean	age	of	64	±	14	years.	All	patients	were	in	NYHA	functional	class	III/IV	before	the	procedure.	
In	3	cases,	PMVR	had	been	performed	as	a	bridge	to	heart	transplant	because	of	the	very	unstable	
conditions	and	the	low	probability	to	have	a	heart	donation	within	a	short	time.	Mean	LVEF	was	
31	±	7	%,	mean	LVEDV	201	±	53	ml,	mean	LVESV	was	141	±	48	ml.	Ten	patients	(40%)	had	
previously	undergone	implantable	cardioverter	defibrillator-CRT	implantation	and	had	been	
subsequently	judged	nonresponders.	STS	mortality	score	was	14±12%,	logistic	EuroSCORE	
29±19%,	depicting	a	very	high-risk	population.	More	than	half	of	the	patients	showed	≥moderate	
renal	failure,	5	(20%)	chronic	obstructive	pulmonary	disease	(COPD),	and	2	patients	(8%)	had	a	
previous	cerebrovascular	accident.	Fourteen	patients	(56%)	had	been	admitted	because	of	heart	
failure	in	the	previous	6	months	(average	number	of	admissions	=	1.7	±1.5).	Ten	patients	(40%)	
were	dependent	from	iv	diuretics,	and	six	patients	(24%)	needed	iv	inotropes	infusion.	Six	patients	
(24%)	had	been	hospitalized	for	an	average	period	of	2	months	at	the	time	of	procedure	because	
they	could	not	be	weaned	from	iv	drugs	infusion.	Average	daily	furosemide	dose	among	
ambulatory	patients	was	178±64	mg.		The	preoperative	median	pro-BNP	value	was	5291	pg/ml	
(interquartile	range,	IQR,	1587-8176	pg/mL).	
	
Acute	results	
In	3	patients	(12%),	coaptation	of	the	mitral	leaflets	was	absent	generating	massive	MR.	In	order	
to	enhance	coaptation	and	facilitate	the	leaflets’	grasp	with	the	Mitraclip	system,	iv	inotropes	
were	initiated	a	few	hours	before	the	procedure	and	in	1	case	intra-aortic	balloon	pump	was	
placed.	No	intraprocedural	complication	occurred	and	no	patient	was	converted	to	conventional	
surgical	mitral	valve	replacement.	In	16%	of	the	patients	1	clip	was	implanted,	in	76%	2	clips	and	in	
8%	3	clips.	Perioperative	outcomes,	in-hospital	and	at	30-day,	are	summarized	in	Table		2.	No	case	
of	“afterload	mismatch”	was	observed.	No	major	bleeding	occurred,	whereas	two	minor	bleedings	
(asymptomatic	microhematuria	in	both	cases)	resolved	spontaneously	before	discharge.	No	
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deaths	nor	adverse	events	after	discharge	up	to	30	days	were	reported.	Pre-discharge	
echocardiography	showed	residual	MR	≤	2+	in	76%	of	the	patients.		
	
Six-month	outcome	
One	patient	died	2	months	after	PMVR	(this	patient	had	a	severe	LV	dysfunction,	LVEDV	250	ml,	
LVEF	18%	and	residual	MR	grade	4).	One	patient	underwent	heart	transplant	around	1	month	
after	the	index	procedure,	and	another	one	received	a	left	ventricular	assist	device	on	an	elective	
basis	(both	patients	underwent	PMVR	as	a	bridge-to-heart	transplant).		
Among	the	other	22	patients,	15/22	patients	(68%)	improved	from	NYHA	functional	class	III	or	IV	
at	baseline	to	NYHA	≤	II.	No	patient	was	in	NYHA	functional	class	IV	(vs.	6/22,	27%	at	baseline)	
(figure	6).	Five	patients	(23%)	were	re-admitted	for	heart	failure.	In	the	first	one,	post-procedural	
mitral	valve	stenosis	(average	gradient	16	mmHg)	had	developed	in	combination	with	known	
severe	COPD.	A	second	patient,	who	was	undergoing	screening	for	heart	transplantation,	had	
residual	MR	grade	3,	22%	LVEF	and	85	mmHg	systolic	pulmonary	pressure.	The	third	patient,	who	
had	been	treated	as	a	bridge	to	heart	transplantation,	had	residual	MR	grade	3,	LVEF	21%	and	
LVEDV	257	ml.	The	fourth	patient,	80	years	old	with	multiple	comorbidities,	was	readmitted	to	
optimize	medical	treatment.	The	fifth	patient	had	end-stage	hypertrophic	cardiomyopathy	with	
severe	LV	dysfunction	and	massive	MR:	in	this	case	intra-aortic	balloon	pump	was	placed	during	
procedure	in	order	to	enhance	coaptation	and	facilitate	the	leaflets’	grasp	with	the	Mitraclip	
system.	On	average,	the	number	of	hospitalizations	for	heart	failure	in	comparison	with	the	6	
months	before	PMVR	were	reduced	from	1.05±1.10	to	0.3±0.7	(p=0.0009)	(figure	7).	Two	patients	
(9%)	without	indication	to	CRT	received	an	ICD	in	primary	prevention	of	sudden	death	because	of	
LVEF	<35%.	Both	patients	showed	a	worsening	of	the	degree	of	mitral	regurgitation	at	six	months	
(from	2+	to	3+).	
	
LV	remodeling	
Six-month	echocardiographic	follow-up	was	available	for	22	patients	(3	excluded	or	missing	were:	
1	death,	1	patient	after	heart	transplant,	1	patient	with	left	ventricular	assist	device.	Changes	from	
baseline	to	6	months	echocardiographic	characteristics	are	summarized	in	Table	3.		MR	≤	2+	was	
reported	in	17	patients	(77%),	whereas	MR	3+	and		MR	4+	in	3	(14%)	and	2	(9%)	of	the	patients	
respectively	(figure	8)	.	There	were	no	significant	changes	from	baseline	in	LVEDV	(195±53	ml	at	
baseline	vs.	193±58	at	6-month,	p=0.90)	and	LVESV	(134±49	ml	at	baseline	vs.	134±51	at	6-month,	
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p=0.54)	or	LVEF	(32±7	%	at	baseline	vs.	32±7	at	6-month,	p=0.35).		No	significant	change	of	these	
parameters	was	observed	considering	only	patients	with	residual	MR≤2	(LVEDV	184±41	ml	at	
baseline	vs.	182±47	at	6-month,	p=0.65;	LVESV	123±37	ml	at	baseline	vs.	123±41	at	6-month,	
p=0.91;	LVEF	33±6	%	at	baseline	vs.	33±6	at	6-month,	p=0.56).	Right	ventricular	function	and	
systolic	pulmonary	artery	pressure	remained	also	unchanged	(table	3).	
	 Measurement	of	pro-BNP	plasma	levels	was	performed	at	baseline	and	at	6	months.	A	
significant	decrease	from	a	median	of	4395	pg/mL	(IQR,	1606-5884	pg/mL)	at	baseline	to	a	median	
of	2594	pg/mL	(IQR,	1406-3924	pg/mL,	P=0.003)	at	follow	up	occurred.		
		
DISCUSSION	
The	present	study	describes	the	results	of	PMVR	with	the	MitraClip	device	in	an	“extreme”	setting	
of	patients	with	severe	FMR.	Indeed,	all	patients	enrolled	presented	chronic	advanced	heart	
failure	with	long	lasting	symptoms	and	were	non	responders	to	optimal	medical	therapy	and	CRT.	
All	patients	had	been	judged	inoperable	because	of	severe	LV	dysfunction	and/or	comorbidities.	
Most	of	them	had	either	massive	mitral	regurgitation,	very	unstable	hemodynamics	and/or	
extreme	LV	remodeling.	In	this	end	stage	setting,	the	Mitraclip	procedure	was	confirmed	to	be	
safe.	In	fact,	no	serious	complication	occurred	neither	in	the	periprocedural	phase	nor	after	6-
month	follow-up.	In	terms	of	efficacy,	improvement	of	symptoms	,	reduction	of	re-admissions	for	
heart	failure	and	favorable	changes	of	neurohormonal	profile	were	evident	despite	any	reverse	LV	
remodeling.		In	previous	studies,	the	effects	of	MitraClip	implantation	in	patients	with	FMR	and	
severe	LV	dysfunction	and/or	heart	failure	have	been	evaluated	heterogeneously.	While	reduction	
of	MR	severity,	of	NYHA	class	and	mortality	have	been	considered	in	all	published	series,	LV	
remodeling	has	been	studied	in	detail	only	in	few	studies16,22,23,29.	Single	studies	have	evaluated	
the	variations	in	6-minute	walking	test	17,23	and	the	neurohormonal	profile	17,22,23.	A	single	paper	
reports	the	variations	in	hospital	admissions	for	heart	failure	after	the	procedure	24.	In	our	study,	
the	simultaneous	availability	of	all	these	parametrs	(except	the	6-minute	walking	test)	allows	
some	pathophysiological	and	methodological	insights	as	well	as	clinical	considerations.	
In	our	series,	the	absence	of	cases	of	acute	post-procedural	afterload	mismatch	despite	a	severe	
baseline	reduction	of	LV	ejection	fraction	is	an	encouraging	observation.	The	issue	of	acute	
afterload	mismatch	has	been	focused	essentially	by	the	S.	Raffaele,	Milan	group.	In	a	series	of	
patients	comparable	to	ours	for	clinical	and	hemodynamic	severity,	Melisurgo	et	al30	report	the	
occurrence	of	afterload	mismatch	with	transitory	hemodynamic	deterioration	in	26%	of	cases.	It	is	
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possible	that	pre-treatment	with	inotropes	of	the	more	severe	cases	in	our	series,	contributed	to	
preventing	the	phenomenon.	
Regarding	mid-term	clinical	outcome,	the	reduction	of	symptoms	and	hospital	admissions	for	
heart	failure	represent	an	important	result	in	a	cohort	of	advanced	heart	failure	patients	with	a	
high	use	of	human	and	economical	resources.	The	observed	reduction	of	NYHA	class		(at	6-months	
no	patient	was	in	NYHA	class	IV,	and	68%	were	in	NYHA	class	≤II	vs.	none	at	baseline,	p<0.001)	is	in	
line	with	the	published	data17,22,23.	Notably,	as	in	the	only	other	available	study	to	investigate	the	
issue	24,	the	number	of	hospitalizations	for	heart	failure	decreased	significantly	in	the	six	months	
following	the	procedure	(from	1.05±1.10	to	0.3±0.7,	p=0.0009,		compared	to	the	6	months	
preceding	PMVR).	This	information	is	potentially	useful	from	a	pharmacoeconomic	standpoint	and	
could	contribute	to	correctly	evaluate	the	net	cost	of	MitraClip	implantation	in	terms	of	quality	of	
life.	
An	important	objective	of	the	study	was	the	evaluation	of	LV	remodeling	and	of	neurohormonal	
changes	during	follow-up.	While	a	significant	decrease	in	NT-pro	BNP	occurred	(from	a	median	
value	of	4395	pg/mL	[interquartile	range	(IQR,	1606-5884	pg/mL]	at	baseline	to	2594	pg/mL	(IQR,	
1406-3924	pg/mL,	P=0.003,	at	6	months),	LV	volumes	remains	substantially	unchanged.		This	is	in	
contrast	with	the	majority	(but	not	the	totality)	of	previous	studies,	that	showed	a	significant	
reduction	of	both	LVEDS	and	LVESV	with	increase	of	LVEF17,22,23,29.	The	reasons	of	this	discrepancy	
is	not	unclear.	Reduction	of	LV	volumes	depends	on	correction	of	volume	overload	and	reverse	
remodeling	is	known	to	occur	mainly	when	MR	severity	is	reduced	to	either	1+	or	2+29.	In	the	
present	study	MR	grades	≤2	persisted	in	the	majority	of	patients	at	6-months.	A	possible	
explanation	could	be	a	somewhat	later	stage	of	the	disease	in	our	series,	although	this	was	not	
completely	captured	by	commonly	used	parameters	of	MR	grade,	LV	dilatation/function	and	risk	
scores.	It	should	be	highlighted	that	all	our	patients	were	recruited	through	an	“advanced	heart	
failure	and	heart	transplantation	program”;	thus	really	end-stage	patients	were	selected,	including	
subjects	already	on	the	waiting	list	for	heart	transplantation	and	patients	who	could	not	be	
weaned	from	iv	diuretics	or	inotropes.	In	one	out	of	six	cases,	coaptation	of	the	mitral	valve	
leaflets	was	so	compromised	that	initiation	of	inotropes,	vasodilators	or	IABP	a	few	hours	before	
the	procedure	was	necessary	in	order	to	accomplish	PMVR.	Another	hypothesis	could	be	the	low	
number	of	observations	and	the	relatively	short	follow-up.	However,	in	our	study	a	“freezing”	of	
LV	volumes	was	confirmed	even	considering	only	patients	with	final	MR	grade	≤2.	Indeed,	our	
results	are	consistent	with	other	small	studies	in	similar	patient	groups.24,31.	
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CONCLUSIONS	
Despite	the	lack	of	reverse	LV	remodeling,	in	our	study	clinical	and	neurohormonal	endpoints	
were	clearly	improved,	delineating	an	overall	positive	clinical	impact	of	PMVR.	In	particular,	the	
average	downgrade	of	NYHA	class	and	the	reduction	of	hospitalizations	for	heart	failure	are	
noteworthy.	In	order	to	impact	LV	remodeling	parameters	as	well,	PMVR	should	be	anticipated	in	
the	natural	history	of	FMR	disease,	as	shown	by	both	PMVR	and	surgical	series32.	Taken	together,	
these	observations	suggest	that	reduction	of	both	NT-pro	BNP	and	NYHA	class	in	conjunction	with	
reversed	or	at	least	halted	LV	remodeling	represent	a	reasonable	end	point	in	the	evaluation	of	
PVMR	treatment	in	patients	with	severe	HF	and	functional	MR.	
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TABLES	
Table	1.	Baseline	clinical,	echocardiographic	and	procedural	characteristics	
Variable	 n=	25	
Age,	y	 64±	14	
Male,	n	(%)	 19	(76)	
NYHA	functional	class,	n	(%)	 	
	 III	 19	(76)	
	 IV	 6	(24)	
Etiology	 	
	 Ischaemic	cardiomyopathy,	n	(%)		 15	(60)	
	 Dilated	cardiomyopathy,	n	(%)		 10	(40)	
Clinical	history	 	
	 Prior	CABG,	n(%)		 5	(20)	
	 Prior	PCI,	n(%)		 13	(52)	
	 Previous	ICD	without	CRT,	n(%)		 7	(28)	
	 Previous	CRT-D,	n	(%)		 10	(40)	
	 Waiting	list	for	heart	transplantation,	n	(%)		 2	(8)	
	 Screening	for	heart	transplantation,	n	(%)		 1	(4)	
Comorbidity	 	
Impired	renal	function	≥	moderate,	n(%)	 15	(60)	
COPD,	n(%)	 5	(20)	
Previous	stroke,	n(%)	 2	(8)	
Diabetes	mellitus,	n	(%)	 8	(32)	
Logistic	EuroScore	(%),mean	±	SD		 	 	 	 29	±	19	
STS	mortality	score	(%),mean	±	SD	 14	±	12	
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Echocardiography	
	 LV	ejection	fraction,	%		 31	±	7	
	 LV	end-diastolic	volume,	ml		 201±	53	
	 LV	end-systolic	volume,	ml		 141±	48	
	 LV	end-systolic	diameter,	mm		 53	±	7	
	 LV	end-systolic	diameter	>	55	mm,	n	(%)			 13	(52)	
	 Systolic	pulmonary	artery	pressure,	mmHg		 49	±	14	
	 Right	ventricle	dilatation	grade	≥	moderate,	n	(%)		 7	(28)	
	 Right	ventricle	dysfunction	grade	≥	moderate,	n	(%)		 11	(44)	
Pro-BNP,	median	[IQR],	pg/ml		 5291	[1587-8176]	
Continuous	variables	are	reported	as	mean	±	standard	deviation	or	median	±	IQR,	categorical	variables	as	
number	(%).	
CABG=	coronary	artery	bypass	graft;	CRT=	cardiac	resynchronization	therapy;	IABP=	intra-aortic	balloon	
pump;	ICD=	implantable	cardioverter	defibrillator;	COPD=	chronic	obstructive	pulmonary	disease;	LV=	left	
ventricular;	PCI=	percutaneous	coronary	intervention.
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Table	2.	Clinical	outcome.	
Variable	 n=25	
In-hospital	 	
	 Death	 0	(0)	
	 AMI,	n	(%)	 0	(0)	
	 Stroke,	n	(%)	 0	(0)	
	 Cardiac	tamponade,	n	(%)	 0	(0)	
	 Conversion	to	cardiac	surgery,	n	(%)	 0	(0)	
	 Major	bleeding,	n	(%)	 0	(0)	
	 Minor	bleeding,	n	(%)	 2	(8)	
	 Need	for	IABP	after	the	procedure,	n	(%)	 0	(0)	
	 Need	for	inotropic	drugs	after	the	procedure,	n	(%)	 0	(0)	
	 Acute	kidney	injury,	n	(%)	 0	(0)	
	 Infection/sepsis,	n	(%)	 0	(0)	
	 Discharge	MR	≤	2+,	n	(%),	 19	(76)	
30-day	mortality,	n	(%)	 0	(0)	
6-month	outcome	 	
	 Death	 1	(4)	
	 AMI	 0	(0)	
	 Stroke	 0	(0)	
	 Heart	transplant/LVAD	 2	(8)	
	 Mitral	valve	surgery	 0	(0)	
AMI=	acute	myocardial	infarction
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Table.3	Changes	from	baseline	to	6	months	in	echocardiographic	characteristics,	neurohormonal	profile	
and	hospital	admissions	
Variable	
	
Baseline	
(n=22)	
6-month	
(n=22)	
P	
Echocardiography	 	 	 	
	 Mitral	regurgitation	grade	≤	2+,	n	(%)	 0	(0)	 17	(77)	 0.00	
	 Mitral	regurgitation	grade≥	3+,	n	(%)	 22	(100)	 5	(23)	 0.00	
	 LV	Ejection	fraction,	mean	±SD	,%	 32	±	7	 32	±	7	 0.35	
	 LV	end-diastolic	volume,	mean	±	SD,	ml	 195±	53	 193±	58	 0.90	
	 LV	end-systolic	volume,	mean	±	SD,	ml	 134±	49	 134±	51	 0.54	
	 LV	end-systolic	diameter,	mean	±	SD,	mm	 52	±	8	 55±	9	 0.12	
	 LV	end-systolic	diameter	>	55	mm,	n	(%)		 11	(50)	 12	(55)	 0.70	
	 Systolic	pulmonary	artery	pressure	mean	±	SD	 49±	15	 43±	12	 0.14	
	 Right	atrial	pressure	mean	±	DS	 9	±	3	 8	±	2	 0.22	
	 Right	ventricular	dilatation	>	moderate,	n	(%)	 7	(32)	 7	(32)	 -	
	 Hypokinetic	right	ventricle	>	moderate,	n	(%)	 9	(41)	 9	(41)	 -	
Clinical	status	 	 	 	
	 NYHA	functional	class	≤	II,	n	(%)	 	 	 0	(0)	 15	(68)	 0.00	
	 NYHA	functional	class	≥	III,	n	(%)	 22	(100)	 7		(32)	 0.00	
Pro-BNP,	median	[IQR],	pg/ml		 4395	[1606-5884]	 2594	[1406-3924]	 0.04	
Hospital	admissions	 	 	 	
	 Total	admissions,	n	(mean±SD)	 1.7	±	1.5†	 0.7	±	0.8	 0.011	
	 Admissions	for	HF,	n	(mean±SD)	 1.05	±	1.1†	 0.3	±	0.7	 0.0009	
†	Hospitalizations	in	the	6	months	before	percutaneous	mitral	valve	repair		
HF=	heart	failure;	IQR=interquartile	range;	NYHA=New	York	heart	association;	pro-BNP=pro-	brain-
natriuretic-peptide;	SD=	standard	deviation.	
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FIGURES	
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Figure	6.	Changes	from	baseline	to	6	months	in	NYHA	functional	class.	Data	refer	to	22	patients	
with	paired	data	at	baseline	and	6-month	follow-up.		
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Figure	7:	Changes	in	hospitalizations	in	the	6	months	before	and	after	percutaneous	mitral	valve	
repair.	Data	refer	to	22	patients	with	paired	data	at	baseline	and	6-month	follow-up.										
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Figure	8.	Changes	from	baseline	to	6	months	in	mitral	regurgitation	(MR)	grade.	Data	refer	to	22	
patients	with	paired	echocardiographic	data	at	baseline	and	6-month	follow-up.	
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